AstraZeneca disclosed a Phase 3 failure of its ATTR-CM silencer, which produced no extra benefit for patients already on a stabilizer, a result that may tilt the market toward stabilizers and ripple through rivals like Alnylam and BridgeBio.
The alleged gunman responsible for the recent mass shootings in Maine had attempted to purchase a silencer for a rifle months before the attacks, but was denied by the firearms store due to his self-incriminating answers on the required form. The store owner believes that if the purchase had been successful, the rampage could have been even deadlier. The shootings, which left 18 dead and 13 injured, have sparked discussions about gun control and mental health regulations. The gunman had previously been committed to a mental health facility but was not forcibly committed, raising questions about the effectiveness of existing regulations.